Cabaletta Bio to Participate in Upcoming Investor Conferences in November and December

Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company, has announced its participation in several key investor conferences scheduled for November and December 2025. These events will provide a platform for the company to showcase its groundbreaking efforts in developing targeted cell therapies aimed at curing autoimmune diseases.

Among the highlighted conferences, Cabaletta will engage in a webcasted fireside chat during Guggenheim’s 2nd Annual Healthcare Innovation Conference on November 11, 2025, at 10:30 a.m. ET in Boston, MA. The company is also available for direct meetings with investors. Following this, they will participate in the TD Cowen Immunology & Inflammation Summit on November 13, 2025, at 11:00 a.m. ET, offering virtual meetings as well.

Moving to international venues, Cabaletta will have a presence at the Jefferies Global Healthcare Conference in London on November 17, 2025, with a fireside chat set for 1:30 p.m. GMT. The company will host meetings with investors until the close of the event on November 18. Additionally, they will take part in the 8th Annual Evercore Healthcare Conference in Coral Gables, FL, on December 2, 2025, and Citi’s Global Healthcare Conference in Miami, FL, on December 3, 2025, both featuring webcasted sessions and investor meetings.

Cabaletta Bio focuses on advancing engineered T cell therapies through its CABA™ platform, which includes their lead product candidate, rese-cel, an investigational therapy being evaluated in the RESET™ clinical program across various therapeutic areas such as rheumatology and dermatology. More information about these developments and upcoming conferences can be found on their website at www.cabalettabio.com.

As Cabaletta Bio, Inc. (Nasdaq: CABA) prepares to participate in various investor conferences over the coming weeks, it presents a significant opportunity for investors to closely monitor developments in the clinical-stage biotechnology sector. The company’s focus on developing curative T cell therapies for autoimmune diseases places it in a compelling niche within the biotech landscape, one that is likely to gain traction given the growing need for innovative treatments in this area.

The company’s participation in multiple conferences, including Guggenheim’s Healthcare Innovation Conference and the Jefferies Global Healthcare Conference, gives prominence to its strategic insights and advancements related to its CABA™ platform and the lead CARTA strategy with the investigational therapy, rese-cel. These conferences will provide the company an essential platform to communicate its progress and engage with potential investors, generating significant visibility.

In particular, the upcoming RESET™ clinical development program evaluations across diverse therapeutic domains highlight the breadth of Cabaletta’s research endeavors. Investors should note the implications of these developments, with a keen eye on any clinical trial updates that could signal positive outcomes and advancements toward market readiness.

Given the speculative nature of clinical-stage biotech investments, the market's response to the outcomes from these conferences could influence CABA's stock trajectory. Investors are advised to consider these upcoming events as critical indicators of the company’s future potential. With replays available for conference presentations, potential investors have an opportunity to analyze Cabaletta’s strategic positioning and impact comprehensively.

As healthcare continues to evolve, investors may find Cabaletta Bio to be an intriguing option, particularly if the company demonstrates solid progress in its clinical trials and maintains effective communication within the investment community during these conferences.